Movement on the germ-warfare front. Eye on Washington
Nirsevimab shows strong real-world effectiveness against RSV in infants
Nirsevimab significantly reduces RSV-related hospitalisations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.
Food Insecurity and the Dangers of Infant Formula Dilution
Full recap from the 2025 Pediatric Academic Societies meeting
In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.
Demystifying Infant Formula
Elamipretide to treat Barth syndrome sees FDA target action delay
Stealth BioTherapeutics' CEO stated, "We hope to gain more information on the revised action date in the coming days."
FDA approves nipocalimab-aahu to treat generalized myasthenia gravis
The human FcRn-blocking monoclonal antibody is indicated for gMG patients aged 12 years and older.
